{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:20:09Z","timestamp":1780406409698,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100005294","name":"Massachusetts General Hospital","doi-asserted-by":"publisher","award":["MGH ECOR"],"award-info":[{"award-number":["MGH ECOR"]}],"id":[{"id":"10.13039\/100005294","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R01HD054599"],"award-info":[{"award-number":["R01HD054599"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R21NS108015"],"award-info":[{"award-number":["R21NS108015"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1038\/s41434-025-00529-6","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T02:37:56Z","timestamp":1743475076000},"page":"89-96","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Early life safety profiling of gene therapy for spinal muscular atrophy"],"prefix":"10.1038","volume":"33","author":[{"given":"Rebecca G.","family":"Spellman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4478-660X","authenticated-orcid":false,"given":"Leillani L.","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9283-6777","authenticated-orcid":false,"given":"Salom\u00e9","family":"Da Silva Duarte Lepez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Arruda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn J.","family":"Swoboda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2646-9689","authenticated-orcid":false,"given":"Christiano R. R.","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"529_CR1","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nrneurol.2018.4","volume":"14","author":"EJN Groen","year":"2018","unstructured":"Groen EJN, Talbot K, Gillingwater TH. Advances in therapy for spinal muscular atrophy: promises and challenges. Nat Rev Neurol. 2018;14:214\u201324.","journal-title":"Nat Rev Neurol"},{"key":"529_CR2","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723\u201332.","journal-title":"N Engl J Med"},{"key":"529_CR3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","volume":"19","author":"T Hagenacker","year":"2020","unstructured":"Hagenacker T, Wurster CD, G\u00fcnther R, Schreiber-Katz O, Osmanovic A, Petri S, et al. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol. 2020;19:317\u201325.","journal-title":"Lancet Neurol"},{"key":"529_CR4","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","volume":"74","author":"D Chand","year":"2021","unstructured":"Chand D, Mohr F, McMillan H, Tukov FF, Montgomery K, Kleyn A, et al. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. J Hepatol. 2021;74:560\u20136.","journal-title":"J Hepatol"},{"key":"529_CR5","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713\u201322.","journal-title":"N Engl J Med"},{"key":"529_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pediatrneurol.2019.06.007","volume":"100","author":"SA Al-Zaidy","year":"2019","unstructured":"Al-Zaidy SA, Mendell JR. From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1. Pediatr Neurol. 2019;100:3\u201311.","journal-title":"Pediatr Neurol"},{"key":"529_CR7","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","volume":"78","author":"JR Mendell","year":"2021","unstructured":"Mendell JR, Al-Zaidy SA, Lehman KJ, McColly M, Lowes LP, Alfano LN, et al. Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol. 2021;78:834.","journal-title":"JAMA Neurol"},{"key":"529_CR8","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1212\/WNL.0000000000008207","volume":"93","author":"BH Lee","year":"2019","unstructured":"Lee BH, Collins E, Lewis L, Guntrum D, Eichinger K, Voter K, et al. Combination therapy with nusinersen and AVXS-101 in SMA type 1. Neurology. 2019;93:640\u20131.","journal-title":"Neurology"},{"key":"529_CR9","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ajhg.2009.08.002","volume":"85","author":"TW Prior","year":"2009","unstructured":"Prior TW, Krainer AR, Hua Y, Swoboda KJ, Snyder PC, Bridgeman SJ, et al. A positive modifier of spinal muscular atrophy in the SMN2 gene. Am J Hum Genet. 2009;85:408\u201313.","journal-title":"Am J Hum Genet"},{"key":"529_CR10","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.omtm.2021.10.011","volume":"23","author":"CRR Alves","year":"2021","unstructured":"Alves CRR, Petrillo M, Spellman R, Garner R, Zhang R, Kiefer M, et al. Implications of circulating neurofilaments for spinal muscular atrophy treatment early in life: a case series. Mol Ther Methods Clin Dev. 2021;23:524\u201338.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"529_CR11","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the phase III SPR1NT trial. Nat Med. 2022;28:1381\u20139.","journal-title":"Nat Med"},{"key":"529_CR12","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nat Med. 2022;28:1390\u20137.","journal-title":"Nat Med"},{"key":"529_CR13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day JW, Finkel RS, Chiriboga CA, Connolly AM, Crawford TO, Darras BT, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20:284\u201393.","journal-title":"Lancet Neurol"},{"key":"529_CR14","doi-asserted-by":"publisher","first-page":"e0213680","DOI":"10.1371\/journal.pone.0213680","volume":"14","author":"SL Lipnick","year":"2019","unstructured":"Lipnick SL, Agniel DM, Aggarwal R, Makhortova NR, Finlayson SG, Brocato A, et al. Systemic nature of spinal muscular atrophy revealed by studying insurance claims. PLOS ONE. 2019;14:e0213680.","journal-title":"PLOS ONE"},{"key":"529_CR15","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000353","volume":"5","author":"FC Nery","year":"2019","unstructured":"Nery FC, Siranosian JJ, Rosales I, Deguise M, Sharma A, Muhtaseb AW, et al. Impaired kidney structure and function in spinal muscular atrophy. Neurol Genet. 2019;5.e353.","journal-title":"Neurol Genet"},{"key":"529_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0613-5","volume":"12","author":"CA Wijngaarde","year":"2017","unstructured":"Wijngaarde CA, Blank AC, Stam M, Wadman RI, van den Berg LH, van der Pol WL. Cardiac pathology in spinal muscular atrophy: a systematic review. Orphanet J Rare Dis. 2017;12. 67.","journal-title":"Orphanet J Rare Dis"},{"key":"529_CR17","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1242\/dev.110.2.547","volume":"110","author":"L Saggin","year":"1990","unstructured":"Saggin L, Gorza L, Ausoni S, Schiaffino S. Cardiac troponin T in developing, regenerating and denervated rat skeletal muscle. Development. 1990;110:547\u201354.","journal-title":"Development"},{"key":"529_CR18","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/clinchem\/43.3.476","volume":"43","author":"GS Bodor","year":"1997","unstructured":"Bodor GS, Survant L, Voss EM, Smith S, Porterfield D, Apple FS. Cardiac troponin T composition in normal and regenerating human skeletal muscle. Clin Chem. 1997;43:476\u201384.","journal-title":"Clin Chem"},{"key":"529_CR19","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2337\/db19-1094","volume":"69","author":"JME Jende","year":"2020","unstructured":"Jende JME, Groener JB, Kender Z, Hahn A, Morgenstern J, Heiland S, et al. Troponin T parallels structural nerve damage in type 2 diabetes: a cross-sectional study using magnetic resonance neurography. Diabetes. 2020;69:713\u201323.","journal-title":"Diabetes"},{"key":"529_CR20","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1093\/clinchem\/43.6.976","volume":"43","author":"MD McLaurin","year":"1997","unstructured":"McLaurin MD, Apple FS, Voss EM, Herzog CA, Sharkey SW. Cardiac troponin I, cardiac troponin T, and creatine kinase MB in dialysis patients without ischemic heart disease: evidence of cardiac troponin T expression in skeletal muscle. Clin Chem. 1997;43:976\u201382.","journal-title":"Clin Chem"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00529-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00529-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00529-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:04:52Z","timestamp":1771977892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00529-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["529"],"URL":"https:\/\/doi.org\/10.1038\/s41434-025-00529-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.11.04.24316576","asserted-by":"object"}]},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"11 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CRRA and KJS are inventors on a patent filed by Mass General Brigham that describes genome engineering technologies to treat SMA. KJS was a recipient of a grant from Biogen and received clinical trial funding from AveXis and Biogen. CRRA is a consultant for Biogen and holds stocks in publicly traded companies developing gene therapies. RGS is a current employee and holds stock\/stock options in Voyager therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval and written informed parental consent were obtained from all participants under Institutional Ethics Review Boards at the Massachusetts General Hospital (protocol 2016P000469).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}